All metastatic NSCLC patients should have molecular testing to identify the presence of driver mutations and actionable targets, like T790M, L858R and exon 19 deletions in EGFR.
The Institut National du Cancer in France developed a special program in 2006 and supported a national network of 28 hospital platforms to organize molecular testing.
Since 2015, NGS implementation had a major impact on laboratory organization and broad genomic sequencing has disseminated ahead of a demonstrated association with better survival, and without economic evaluation.
We decided to evaluate the MassARRAY technology, an open platform, for lung cancer, breast and colon tumors or melanoma, in comparison with NGS.
Here, Dr. Pencreach will present the results of their retrospective technical analysis after one year of routine NSCLC molecular testing with the MassARRAY System from a biological/clinical and economical point of view.
Erwan Pencreach, PharmD, PhD, Department of Molecular Oncology, Strasbourg University Hospital, France
University lecturer / associate professor – Hospital practitioner Strasbourg Faculty of Medicine and University Hospital, Strasbourg (France)